Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)

September 12, 2022

https://www.globenewswire.com/news-release/2022/09/12/2513866/0/en/Allakos-Announces-Initiation-of-Phase-2b-Clinical-Trial-of-Subcutaneous-Lirentelimab-in-Chronic-Spontaneous-Urticaria-CSU.html

SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Allakos Inc. (Nasdaq:ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced it has initiated a Phase 2b clinical trial to evaluate the efficacy, safety and tolerability of subcutaneous lirentelimab in patients with chronic spontaneous urticaria (MAVERICK). Top-line results from the trial are expected in the second half of 2023.

Read more at globenewswire.com

Related news for (ALLK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.